On May 31th Gelun Hui | gtja's research report pointed out that Gan & Lee Pharmaceuticals (603087.SH) has achieved a new breakthrough in its products going global, and its production line has passed the European Union GMP inspection. In addition, all of the company's products in the centralized procurement have been bid on with price increases, and expected to bring in thicker profits. GLP-1 data will be disclosed soon, and the R&D pipeline continues to advance. Maintain a "shareholding" rating. The GLP-1 receptor agonist GZR18, which the company independently researched and developed, has completed Phase Ib/IIa clinical trials in adults with type 2 diabetes and adult weight management, respectively, and has achieved its main endpoint and all secondary data endpoints. In addition, the company's gan & lee insulin, laipu insulin, and mendong insulin are in the market approval phase in the United States and Europe.
研报掘金丨国泰君安：维持甘李药业增持”评级，研发管线持续推进
Research Nuggets丨Guotai Junan: Maintaining the “Gan Li Pharmaceutical Gains” Rating, R&D Pipeline Continues to Advance
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.